Literature DB >> 21775522

Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel.

Ahmed Ashour Ahmed1, Xiaoyan Wang, Zhen Lu, Juliet Goldsmith, Xiao-Feng Le, Geoffrey Grandjean, Geoffrey Bartholomeusz, Bradley Broom, Robert C Bast.   

Abstract

The extracellular matrix protein TGFBI enhances the cytotoxic response of cancer cells to paclitaxel by affecting integrin signals that stabilize microtubules. Extending the implications of this knowledge, we tested the more general hypothesis that cancer cell signals which increase microtubule stability before exposure to paclitaxel may increase its ability to stabilize microtubules and thereby enhance its cytotoxicity. Toward this end, we carried out an siRNA screen to evaluate how genetic depletion affected microtubule stabilization, cell viability, and apoptosis. High content microscopic analysis was carried out in the absence or presence of paclitaxel. Kinase knockdowns that stabilized microtubules strongly enhanced the effects of paclitaxel treatment. Conversely, kinase knockdowns that enhanced paclitaxel-mediated cytotoxicity sensitized cells to microtubule stabilization by paclitaxel. The siRNA screen identified several genes that have not been linked previously to microtubule regulation or paclitaxel response. Gene shaving and Bayesian resampling used to classify these genes suggested three pathways of paclitaxel-induced cell death related to apoptosis and microtubule stability, apoptosis alone, or neither process. Our results offer a functional classification of the genetic basis for paclitaxel sensitivity and they support the hypothesis that stabilizing microtubules prior to therapy could enhance antitumor responses to paclitaxel treatment. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775522      PMCID: PMC3679477          DOI: 10.1158/0008-5472.CAN-11-0025

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Phosphorylation of microtubule-associated protein tau by Ca2+/calmodulin-dependent protein kinase II in its tubulin binding sites.

Authors:  Hideyuki Yamamoto; Emiko Yamauchi; Hisaaki Taniguchi; Tsunehiko Ono; Eishichi Miyamoto
Journal:  Arch Biochem Biophys       Date:  2002-12-15       Impact factor: 4.013

2.  Suppression of tubulin polymerization by the LKB1-microtubule-associated protein/microtubule affinity-regulating kinase signaling.

Authors:  Yasushi Kojima; Hiroyuki Miyoshi; Hans C Clevers; Masanobu Oshima; Masahiro Aoki; Makoto M Taketo
Journal:  J Biol Chem       Date:  2007-06-15       Impact factor: 5.157

Review 3.  The ATR pathway: fine-tuning the fork.

Authors:  Renee D Paulsen; Karlene A Cimprich
Journal:  DNA Repair (Amst)       Date:  2007-05-24

Review 4.  Regulation and function of IKK and IKK-related kinases.

Authors:  Hans Häcker; Michael Karin
Journal:  Sci STKE       Date:  2006-10-17

5.  The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.

Authors:  Daniel G Rosen; Imelda Mercado-Uribe; Gong Yang; Robert C Bast; Hesham M Amin; Raymond Lai; Jinsong Liu
Journal:  Cancer       Date:  2006-12-01       Impact factor: 6.860

6.  Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.

Authors:  Jian-Zhi Wang; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Eur J Neurosci       Date:  2007-01       Impact factor: 3.386

7.  Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

Authors:  Roman Rouzier; Radhika Rajan; Peter Wagner; Kenneth R Hess; David L Gold; James Stec; Mark Ayers; Jeffrey S Ross; Peter Zhang; Thomas A Buchholz; Henry Kuerer; Marjorie Green; Banu Arun; Gabriel N Hortobagyi; W Fraser Symmans; Lajos Pusztai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-24       Impact factor: 11.205

Review 8.  Microtubules and maps.

Authors:  Linda A Amos; Daniel Schlieper
Journal:  Adv Protein Chem       Date:  2005

Review 9.  Weekly administration of paclitaxel: theoretical and clinical basis.

Authors:  Paolo Marchetti; Saïk Urien; Giancarlo Antonini Cappellini; Graziana Ronzino; Corrado Ficorella
Journal:  Crit Rev Oncol Hematol       Date:  2002-12-27       Impact factor: 6.312

10.  Repeat motifs of tau bind to the insides of microtubules in the absence of taxol.

Authors:  Santwana Kar; Juan Fan; Michael J Smith; Michel Goedert; Linda A Amos
Journal:  EMBO J       Date:  2003-01-02       Impact factor: 11.598

View more
  26 in total

1.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

2.  Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.

Authors:  Joshua J Souchek; Amanda L Davis; Tanner K Hill; Megan B Holmes; Bowen Qi; Pankaj K Singh; Steven J Kridel; Aaron M Mohs
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

3.  Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing.

Authors:  Mei-Chong Wendy Lee; Fernando J Lopez-Diaz; Shahid Yar Khan; Muhammad Akram Tariq; Yelena Dayn; Charles Joseph Vaske; Amie J Radenbaugh; Hyunsung John Kim; Beverly M Emerson; Nader Pourmand
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-22       Impact factor: 11.205

4.  Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.

Authors:  Elizabeth H Stover; Maria B Baco; Ofir Cohen; Yvonne Y Li; Elizabeth L Christie; Mukta Bagul; Amy Goodale; Yenarae Lee; Sasha Pantel; Matthew G Rees; Guo Wei; Adam G Presser; Maya K Gelbard; Weiqun Zhang; Ioannis K Zervantonakis; Patrick D Bhola; Jeremy Ryan; Jennifer L Guerriero; Joan Montero; Felice J Liang; Andrew D Cherniack; Federica Piccioni; Ursula A Matulonis; David D L Bowtell; Kristopher A Sarosiek; Anthony Letai; Levi A Garraway; Cory M Johannessen; Matthew Meyerson
Journal:  Mol Cancer Res       Date:  2019-08-28       Impact factor: 5.852

5.  Digging deep and wide into single cells.

Authors:  Vivien Marx
Journal:  Nat Methods       Date:  2012-12-07       Impact factor: 28.547

Review 6.  Molecular approaches to personalizing management of ovarian cancer.

Authors:  R C Bast
Journal:  Ann Oncol       Date:  2011-12       Impact factor: 32.976

7.  Mechanical aspects of microtubule bundling in taxane-treated circulating tumor cells.

Authors:  MunJu Kim; Katarzyna A Rejniak
Journal:  Biophys J       Date:  2014-09-02       Impact factor: 4.033

8.  Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP.

Authors:  Xuemei Xie; Chandra Bartholomeusz; Ahmed A Ahmed; Anna Kazansky; Lixia Diao; Keith A Baggerly; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2013-03-29       Impact factor: 6.261

9.  6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.

Authors:  Hailing Yang; Zhang Shu; Yongying Jiang; Weiqun Mao; Lan Pang; Abena Redwood; Sabrina L Jeter-Jones; Nicholas B Jennings; Argentina Ornelas; Jinhua Zhou; Cristian Rodriguez-Aguayo; Geoffrey Bartholomeusz; LaKesla R Iles; Niki M Zacharias; Steven W Millward; Gabriel Lopez-Berestein; Xiao-Feng Le; Ahmed A Ahmed; Helen Piwnica-Worms; Anil K Sood; Robert C Bast; Zhen Lu
Journal:  Clin Cancer Res       Date:  2019-08-07       Impact factor: 12.531

Review 10.  Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.

Authors:  Ignacio Romero; Robert C Bast
Journal:  Endocrinology       Date:  2012-03-13       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.